Investors have recently focused on the NCE status forĀ Amarin's (NASDAQ: AMRN) triglyceride-lowering drug Vascepa and potential suitors for the company, but many might be overlooking a topic that is essential to the future of this biotech stock: patents.

A cascade of patents protecting Vascepa from generic competitors has been rolling in lately, and Amarin is keen on obtaining more IP for its flagship product. In this video, health-care analysts Max Macaluso and Brenton Flynn talk about the drug's latest patents, and discuss why they are so vital for Amarin today.

Brenton Flynn and Max Macaluso, Ph.D. have no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.